X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to optimize the development of Oregon's first-in-class protein disulfide isomerase inhibitor, XCE853 in novel and targeted cancer indications by leveraging Lantern's proprietary RADR® AI platform.
Lead Product(s): XCE853
Therapeutic Area: Oncology Product Name: XCE853
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oregon Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 06, 2024
Details:
Dimesna (LP-300) is a cancer causing TK’s proteins and receptors inactivator, is being investigated in non-small cell lung cancer (NSCLC) in never-smokers in both Japan and Taiwan.
Lead Product(s): LP-300,Pemetrexed,Carboplatin
Therapeutic Area: Oncology Product Name: Dimesna
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2024
Details:
LP-284 is a novel small molecule with a synthetically lethal mechanism of action that preferentially damages cancer cells that harbor mutations in DNA damage repair pathways. It is being evaluated for relapsed or refractory non-Hodgkin’s lymphoma and other solid tumors.
Lead Product(s): LP-284
Therapeutic Area: Oncology Product Name: LP-284
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2024
Details:
LP-284 is a novel small-molecule, next-generation acylfulvene, which is currently being evaluated for the treatment of High-Grade B-cell Lymphomas (HGBL).
Lead Product(s): LP-284
Therapeutic Area: Oncology Product Name: LP-284
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2023
Details:
LP-184 is a small molecule drug candidate that is highly potent and synthetically lethal in solid tumors, harboring defects in multiple DNA damage repair and recombination pathways (HR/NER).
Lead Product(s): LP-184
Therapeutic Area: Oncology Product Name: LP-184
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2023
Details:
LP-284 is a novel small molecule with a synthetically lethal mechanism of action that preferentially damages cancer cells that harbor mutations in DNA damage repair pathways, which is investigated for the treatment of non-hodgkin’s lymphomas.
Lead Product(s): LP-284
Therapeutic Area: Oncology Product Name: LP-284
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
LP-184 (Irofulven) is a small molecule drug candidate that is highly potent and synthetically lethal in solid tumors, harboring defects in multiple DNA damage repair and recombination pathways (HR/NER).
Lead Product(s): LP-184,Undisclosed
Therapeutic Area: Oncology Product Name: LP-184
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2023
Details:
LP-184 is a small molecule drug candidate that is highly potent and synthetically lethal in solid tumors, harboring defects in multiple DNA damage repair and recombination pathways (HR/NER).
Lead Product(s): LP-184
Therapeutic Area: Oncology Product Name: LP-184
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2023
Details:
Under the collaboration, Lantern will leverage its proprietary AI platform, RADR®, to rapidly develop novel cryptophycin-antibody drug conjugates, which represent an exciting class of potent and highly targeted drug candidates, with high therapeutic and antitumor potential.
Lead Product(s): Cryptophycin Antibody-drug Conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bielefeld University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 08, 2023
Details:
Under the agreement, Reprocell will provide support for Lantern Pharma's Phase 2 trial of LP-300 (tavocept) in combination with carboplatin and pemetrexed in patients who are never smokers with lung adenocarcinoma and have relapsed after treatment with TKIs.
Lead Product(s): Dimesna,Pemetrexed,Carboplatin
Therapeutic Area: Oncology Product Name: LP-300
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Reprocell
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 03, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
